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Osteoarthritis is the most common arthritic condition, which involves progressive degeneration of articular cartilage. The most
recent accomplishments have signiﬁcantly advanced our understanding on the mechanisms of the disease development and
progression.Themostintriguing isthegrowingevidenceindicatingthatextracellular matrixdestruction inosteoarthriticarticular
cartilage resembles that in the hypertrophic zone of fetal growth plate during endochondral ossiﬁcation. This suggests common
regulatory mechanisms of matrix degradation in OA and in the development and can provide new approaches for the treatment
of the disease by targeting reparation of chondrocyte phenotype.
1.Introduction
Osteoarthritis (OA)is themost commonjoint disease, which
is associated with a risk of mobility disability. It aﬀects
approximately 12% of the aging Western population, while a
quarter of people aged over 55 have an episode of persistent
knee pain [1]. The pathology of OA involves the whole
joint and is associated with focal and progressive hyaline
articular cartilage loss, concomitant sclerotic changes in the
subchondral bone, and the developmentof osteophytes. Soft
tissuestructuresinandaroundthejoint includingsynovium,
ligaments, and muscles are also involved [2].
OA aﬀects predominantly articular cartilage, which
degrades by gradual loss of its extracellular matrix (ECM)
composed mainly of aggrecan and type II collagen. Loss of
large proteoglycan aggrecan decreases cartilage compressive
stiﬀness and precedes the damage to collagen ﬁbrillar
network, which is responsible for tensile properties of the
tissue [3]. Aggrecan degradation is associated with upreg-
ulation of aggrecanases a disintegrin and metalloprotease
with thrombospondin motifs (ADAMTS-) 4 and 5 as well
as matrix metalloproteinases (MMPs) [4]. The excessive
cleavage of type II collagen in OA is assumed to be
caused by the upregulation of the synthesis and activities of
collagenases [5–7], in particular MMP-13 [8–10]. Presently,
it is believed that articular cartilage destructionin OA results
from excessive loading, age-related changes, and metabolic
i m b a l a n c ei nt h et i s s u e[ 11–13].
OA also exhibits features of a systemic disease as it has
been shown to involve vascular pathology [14, 15]a sw e l l
as T-cell immune response [16, 17] associated with upreg-
ulation of cytokines such as interleukin (IL-) β and tumor
necrosis factor (TNF)α [3, 18], which aggravate cartilage
resorption [19].Asthemechanism ofOA developmentis not
completely understood, the disease manifestations, which
are associated with cartilage resorption and inﬂammation,
suggest a treatment involving inhibition of proinﬂammatory
cytokines or MMP activity to prevent matrix destruction.
However, it does not result in disease modiﬁcation and
produces severe side eﬀects [20, 21].
Articular cartilage degeneration in OA is also associated
with changes in chondrocyte phenotype [13, 22, 23]. Specif-
ically, these changes resemble those observed during chon-
drocyte diﬀerentiation in endochondral ossiﬁcation and are
characterized by cell cloning, expression of diﬀerentiation-
related genes such as parathyroid hormone-related peptide
(PTHrP) [24], type X collagen [25–27], annexins and
alkaline phosphatase (ALP)[28,29],osteocalcin[30],matrix
calciﬁcation [31, 32], as well as apoptotic cell death of
terminally diﬀerentiated chondrocytes [33, 34]. All these2 Arthritis
cellular changes including increased cleavage of type II
collagen by MMP-13 are also associated with chondrocyte
hypertrophy observed in the growth plate [35]. This suggests
that, as articular cartilage shares a common embryological
origin with the epiphyseal growth plate [36], destruction
of cartilage matrix in OA may involve some of the same
cellular and regulatory mechanisms that govern normal
chondrocyte terminal diﬀerentiation and ECM resorption in
skeletal growth and repair [22].
The aim of this paper is to summarize current evi-
dence supporting the involvement of molecular mechanisms
observed in the course of chondrocyte progression through
the growth plate in cartilage matrix destruction in OA.
2.Zonal Gene ExpressioninEpiphyseal
GrowthPlate
A central process in endochondral bone formation is a
progressivediﬀerentiationofproliferatingmatrix assembling
chondrocytes to growth-arrested hypertrophic cells. This
involves remodeling and mineralization of the cartilage
matrix and leads eventually to its subsequent replacement by
bone.
Primary mammalian growth plate physis is structurally
organized and can be divided into zones, namely, the resting,
proliferative, and hypertrophic. Resting zone chondrocytes
showverylimited celldivision evidencedbylowproliferating
cell nuclear antigen (PCNA) expression [37]. They elaborate
an extensive extracellular matrix, which is composed pre-
dominantly of type II collagen and proteoglycan aggrecan;
however, it also contains other collagen types VI, IX, XI,
link protein, and small leucine-rich proteoglycans (SLRPs)
such as decorin and ﬁbromodulin [37]. Expression of several
regulatory growth factors, such as bone morphogenetic pro-
teins (BMPs-) 3, 5, 7, ﬁbroblast growth factor (FGF-) 2, and
transforming growth factor (TGF)β1–3 has been detected in
this zone as well [37–43].
In contrast to resting zone, proliferative zone chondro-
cytes actively divide, which is evidenced by the expression of
cyclins [35, 44] and the presence of PCNA positive cells [45].
They produce long columns of ﬂattened cells and express
hyaline ECM similar to resting zone chondrocytes. The space
for the cells newly formed in the course of cell division is
generated by the matrix-degrading activity of collagenases
MMP-13, MT1-MMP [46, 47], and other MMPs such as
MMP-3 [48]. These cells also express proliferation-speciﬁc
growth factors, namely, TGFβ1–3, FGF-2 [35, 43, 49, 50],
PTHrP, insulin growth factor (IGF-) I and II [35, 51–53],
a cell death inhibitor that regulates apoptosis Bcl-2 (B-cell
lymphoma-2) [54], and transcription factor Sox9 (SRY-type
high-mobility-group box transcription factor 9) [35, 55].
AlthoughPTHrP [56], TGFβ2,and FGF-2 [57,58]havebeen
reported to stimulate MMP-13 expression in rodents, in the
early proliferative zone of the growth plate, their expression
does not induce signiﬁcant matrix loss probably due to the
lack of gelatinase (MMP-2 and -9) expression [35, 59].
Cessation ofcell division in the growth plate isassociated
with upregulation of cell cycle inhibitors p18, p19, and p21
[60], growth arrest and DNA damage-inducible (GADD)
45beta gene [61, 62], as well as apoptosis inhibitors Bcl2 and
Bag1 (Bcl2-associated athanogene 1), a Bcl2-binding protein
capable of enhancing Bcl2 activity [42, 63], and a marker of
apoptosiscaspase3[42].Atthispoint,chondrocytespartially
resorb their extracellular matrix, enlarge, round up, and
ﬁnally mature into hypertrophic cells, which express type X
collagen (COL10A1), a marker of chondrocyte hypertrophy.
Alkalinephosphataseshowsthemostpronouncedexpression
also in hypertrophic chondrocytes [64, 65]. This phenotypic
modiﬁcation in growth plate chondrocytes is associated with
dramatic alteration in regulatory gene expression, namely,
upregulation of growth factors such as TGFβ1a n d- 3[ 35,
50], BMP-2, -4, -6, and -7 [39, 40, 66–68], connective tissue
growth factor (CTGF) [69], vascular endothelial growth
factor (VEGF) [59, 70], and Indian hedgehog (Ihh) [35,
71, 72]. Inﬂammation-related cytokine IL-1 expression also
has been observed only in the hypertrophic chondrocytes
[73].
These regulatory growth factors are expressed in asso-
ciation with runt-related transcription factor (RUNX)2,
which is essential both for osteoblast diﬀerentiation [74]a n d
chondrocyte maturation during endochondral ossiﬁcation
[75–78], and is capable of inducing MMP-13 expression
[79, 80].
Expression of these growth and transcription factors is
also associated with upregulation of matrix proteins, such
as collagen type II (COL2A1) concomitantly with their
degrading enzymes MMP-13 and gelatinases MMP-2 and -
9[ 35, 67]. At this time, overt type II collagen degradation
occurs [46] indicating that genes for both matrix synthesis
and degradation are coregulated. However aggrecan remains
retained in the tissue at that time [3].
In the lower hypertrophic zone, mineralization (or
calciﬁcation) of residual matrix remaining after its resorp-
tion is initiated focally [3]. This involves deposition of
hydroxyapatite mineral [81]. Mineralization process in the
lower hypertrophic zone of the growth plate is associated
with expression of osteocalcin, which is a marker of mature
osteoblasts and is involved in chondrocyte mineralization
and Ca+2 homeostasis [28]. Upregulation of ankylosis pro-
tein (Ank), which is responsible for transport of intracellular
inorganic pyrophosphate to the extracellular milieu, has
been also observed in this zone [82]. Mineralization is
likely regulated by annexins II, V, and VI, which are highly
expressed in the hypertrophic and terminally diﬀerentiated
mineralizing growth plate chondrocytes and form calcium
channels enabling formation of ﬁrst mineral phase [83, 84].
For example, annexin V has been shown to be capable of
upregulating annexins II, VI, osteocalcin, Runx2, and ALP
as well as stimulating apoptotic activity in the lowest part of
the growth plate [83, 85]. In contrast, TGFβ2, which is also
expressed by lower hypertrophic chondrocytes [35], is most
probably involved in osteoblast formation [86].
Therefore, chondrocytematurationinthe growthplateis
associated with expression of stage-speciﬁc set of regulatory
growth and transcription factors producing changes in
cellular phenotype and synthesis of stage-speciﬁc extracel-
lular matrix, which eventually degrades in the hypertrophicArthritis 3




Chondrocyte diﬀerentiation is initiated in the center of the
cartilaginous bone rudiment and is thought to be induced
by hypoxia and/or nutrient deﬁciency [87] .T h ep a c eo f
chondrocyte diﬀerentiation is regulated by various agents
including paracrine and autocrine growth factors and hor-
mones [3, 88]. They are responsible for speciﬁc regulatory
molecule expression by chondrocytes in the course of their
progression through the growth plate.
Growth factors secreted by fetal chondrocytes are in
charge of mutually exclusive processes of chondrocyte pro-
liferation and terminal diﬀerentiation. Thus, proliferation-
related growth factors such as basic ﬁbroblast growth factor
and parathyroid hormone-related peptide stimulate resting
chondrocytes to proliferate and suppress terminal diﬀeren-
tiation of hypertrophic chondrocytes [89–96]. In addition,
PTHrP, in combination with Indian hedgehog, regulates
chondrocyte diﬀerentiation through the establishment of
a negative feedback mechanism, whereby Ihh and PTHrP
can together suppress hypertrophy [97–100]. Alternatively,
interactions ofIhh with syndecan 3, which serves as a growth
factor coreceptor, are important for restricting mitotic
activity to the proliferative zone of mammalian growth plate
[101].
Transforming growth factor betas are multifunctional
molecules regulating cellular proliferation, diﬀerentiation,
and extracellular matrix function [75, 102]. TGFβ trans-
ported from apoptotic chondrocytes to the region of cell
division would be expected to stimulate matrix production,
delayhypertrophicdiﬀerentiation,andthusmaintain growth
plate width [103, 104]. TGFβ1[ 105–107]a n dT G F β2
[108] each are able to suppress chondrocyte hypertrophy
by coordinate inhibition of collagenase expression. This
is partially associated with upregulation of PTHrP gene
expression that exerts both PTHrP-dependent and PTHrP-
independent eﬀects on endochondral bone formation [105,
109, 110]. TGFβ2 in synergy with FGF-2 has been also
shown tosuppresschondrocytematurationandhypertrophy
[111, 112].
BMP signaling is also essential for chondrocyte progres-
sion through the growth plate [66]. Zone speciﬁc expression
of various BMPs suggests their involvement in chondrocyte
phenotypic changes in the course of both proliferation
and hypertrophy. Thus, BMP-2 and -6 have been shown
to promote chondrocyte hypertrophy by upregulation of
Ihh and type X collagen expression and downregulation
of FGF signaling involving Runx2 [113–118]. At the same
time, BMP-2 and -9 augmented mitogenic eﬀect of IGF-1,
while BMP-5 increased cell proliferationand cartilage matrix
synthesis [119, 120].
IGF-1, a structural and functional analog of insulin, pro-
motes chondrocyte proliferation and diﬀerentiation while
it inhibits apoptosis [89, 93]. It is also an important
regulator of PTHrP-Ihh feedback loop. The lack of IGF
resultsindownregulationofIhhexpressionandupregulation
of PTHrP [51]. IGF-1 favors chondrocyte hypertrophic
development as it induced type X collagen and alkaline
phosphatase in avian sternal chondrocytes [108, 112]. In
addition,insulinandIGF-1[121] bothare strong stimulators
of aggrecan and type II collagen synthesis [122].
Furthermore, chondrocyte diﬀerentiation in the growth
plate is regulated by various transcription factors [123].
Transcription factors Sox9 and -4 have been shown to
determine the rate of chondrocyte diﬀerentiation into
hypertrophy and the expression of chondrocyte-speciﬁc
matrix molecules including Col2A1, Col9A2, Col11A1, and
aggrecan [124–130]. They are also required to prevent
conversion of proliferating chondrocytes into hypertrophic
chondrocytes [55]. Transcription factors Runx1-3 are the
most important as they play a crucial role both in chon-
drocyte maturation and had been shown to induce MMP-
13 expression [77, 80, 125, 131]. Recently, the involvement
of several other transcription factors such as Shox/Shox2,
Dlx5, and MEF2C has been shown to control skeletal growth
thatsuggeststheirpotentialcontributioninectopicchondro-
cyte hypertrophy development[132, 133]. Wnt/beta-catenin
signaling can also mediate chondrocyte hypertrophy as it is
capable of upregulating type X collagen, Runx2, and alkaline
phosphatase expression while inhibiting Sox9 and type II
collagen expression [92].
Prostaglandin E2 (PGE2), a potent lipid molecule that
regulates a broad range of physiologic reactions, can inhibit
growth plate chondrocyte diﬀerentiation by downregulation
of diﬀerentiation-related genes COL10A1, VEGF, MMP-
13, and alkaline phosphatase expression as well as their
enzyme activity [134, 135]. At the same time, low con-
centrations of this prostaglandin are capable of increasing
proliferation of growth plate chondrocytes [136, 137]. In
contrast, chemokine stromal sell-derived factor 1, annexin
V, and Ank have been shown to stimulate hypertrophy,
mineralization, and apoptosis, when they are overexpressed
in nonmineralizing growth plate chondrocytes [82, 85, 138,
139].
Extracellular matrix proteins produced by chondrocytes
have also exhibited a capacity to regulate growth plate
chondrocyte hypertrophy. Thus, type II collagen, aggrecan,
and matrilin-3 are likely to inhibit hypertrophy as these
matrix component deﬁciency produced premature mat-
u r a t i o ni nm u t a n tc h o n d r o c y t e s[ 140–142]. Furthermore
a functional link between chondrocyte hypertrophy and
extracellular matrix degradationis also supported by the fact
that downregulation of chondrocyte hypertrophy evidenced
by suppression of type X collagen, Runx2 and MMP-13
expression is associated with inhibition of collagen cleavage
activity in cultured hypertrophic growth plate chondrocytes
treated with MMP-13 inhibitor [8, 143, 144]. This indicates
a functional link between chondrocyte hypertrophy and
extracellular matrix degradation.
It is necessary to note that variable eﬀects of regulatory
molecules are carefully coordinated to provide accuracy in
the process of endochondral ossiﬁcation. Thus, it has been
demonstrated that growth plate chondrocyte progression4 Arthritis
to hypertrophy is a subject to negative control that can
be arrested at various checkpoints [112]. Accordingly, an
early proliferative phenotype in avian fetal chondrocytes
has been reassumed by treatment with TGFβ2, FGF-2, and
insulin in combination, while diﬀerential Ihh expression was
responsible foracquisitionofthelateproliferativephenotype
in hypertrophic cells [112]. In another study, the release
of terminally diﬀerentiated hypertrophic chondrocytes from
their environment also resulted in downregulation of type X
collagen synthesis, activation of proliferation, and reinitia-
tion of aggrecan synthesis [145].
Therefore, chondrocyte diﬀerentiation is carefully regu-
lated in the course of endochondral ossiﬁcation. Eventually,
epiphysealchondrocytesgiverisetoarticularcartilage,whose
structural components and regulatory networks at least
partially resemble that in the growth plate.
4.Zonal Gene ExpressioninHealthy
ArticularCartilage
Healthy articular cartilage is characterized by a very low
expression of collagens type II, VI, IX, and XI [146]a n d
relatively high turnover rate for aggrecan [147]. It is also
characterized by expression of matrix turnover genes such
as MMP-3 [148], occasionally detected MMP-1, -8, -13
[149], and growth factors TGFβ1[ 150]a n dP T H r P[ 24,
151]. Antiangiogenic factor chondromodulin-1 [152, 153],
p16INK4α, and Gadd45α/β genes, the latter is associated
with environmental and intrinsic stress [154, 155], are
expressed in all the cartilage zones. At the same, time no
expression of type I and X collagens [156, 157], a complete
lack of expression of TGFβ2, IGF-1, Ihh [158, 159], annexin
VIII [160], and osteocalcin [30] was observed in healthy
cartilage.
Articular cartilage can be divided into superﬁcial, mid-,
anddeepzones;thelatterisfollowed bythecalciﬁedcartilage
providing junction of the cartilage to the subchondral bone
[157]. These zones diﬀer in expression of speciﬁc matrix
molecules, their modifying enzymes, and regulatory growth
factors, which are responsible for articular cartilage integrity
and function. Although normal articular chondrocytes are
less metabolically active than the growth plate chondrocytes,
some similarity in gene expression pattern in the individual
cartilage zones has been noted.
Superﬁcial zone of healthy articular cartilage contains
ﬂattened chondrocytes surrounded by specialized extracel-
lular matrix rich in thin collagen ﬁbrils [161]a n ds m a l l
leucine-rich proteoglycans-decorin and biglycan [162]. It
also contains the lowest amount of predominant cartilage
proteoglycan aggrecan compared to other zones of articular
cartilage. This zone is rich in regulatory molecules such
as TGFβ1a n d- 3a n dB M P1 – 6[ 37, 40]. Proliferative
potential of these cells is indicated by the expression of
cyclin D2; however, it may be suppressed by cell division
inhibitors such as growth arrest speciﬁc protein (Gas)-1 and
Gadd45α, which are also expressed in this cartilage zone
[37]. This is supported by the lack of superﬁcial chondrocyte
proliferative activity determined by PCNA staining [163].
MMP-3 expression was observed in this cartilage zone more
oftenthan MMP-1, -8, and-13,howevertheseproteinases do
not produce any matrix degradation and are likely involved
in matrix turnover [149, 164]. Expression of antiapoptotic
Bcl2and Bag1geneswasdetectedpredominantly inthiszone
in old mice, while it was observed throughout the articular
cartilage in the young animals [63].
Mid-zone chondrocytes are round in shape, surrounded
by ECM composed of thick collagen ﬁbrils and rich in
aggrecan. Chondrocytes in this zone do not show any
proliferative activity determined by PCNA staining similar
to superﬁcial zone cells [163]. However, these cells are likely
to possess a potential for proliferation, as FGF-2, capable
of inducing proliferation in normal articular chondrocytes
in culture [165], has been detected in the mid-zone of
mouse articular cartilage [49]. BMP1–7 expression was also
observed in the mid-zone of normal articular cartilage
[40].
Deep zone chondrocytes are grouped in clusters and
resemble hypertrophic chondrocytes of the growth plate [3].
In this zone, cartilage matrix has the highest content of
aggrecan [166], the lowest amounts of small leucine-rich
proteoglycans [162], and the largest diameter of collagen
ﬁbrils. Similar to hypertrophic zone of the growth plate,
BMP1–7 [40], Ihh expression [167], and the highest amount
of annexin VI-positive cells were observed in the deep
zone of human articular cartilage [163]. The lowest part
of the deep zone, which is partly calciﬁed, expressed a
marker of chondrocyte hypertrophy type X collagen and
is rich in alkaline phosphatase. MMP-13 expression [149]
and negligible activity of chondrocyte apoptosis was also
sometimes observed here [168, 169].
However, in spite of low activity of cellular and matrix
turnover, healthy articular cartilage possesses a strong
metabolic potential, whose activation is observed during
development of pathological condition such as OA.
5.EarlyDevelopmentofOsteoarthritis
Early OA changes in articular cartilage are associated with
signiﬁcant metabolic activation of articular chondrocytes.
This involves sequential and zonal upregulation of chondro-
cyte diﬀerentiation-related genes as well as an increase in
the activity of the same MMPs, which are responsible for
matrix degradation in the hypertrophic zone of the growth
plate. Spatially, these genes are upregulated in the mid- and
superﬁcial zones of articular cartilage, where lately the ﬁrst
signs of cartilage destruction occur.
Mild OA changes (Mankin 1–4) are characterized by the
loss of proteoglycans in the surface area [163, 170, 171].
Although these changes were not accompanied by signiﬁcant
structural disturbances in the tissue, they were associated
with increased type II collagen and aggrecan synthesis,
upregulation of chondrocyte proliferation evidenced by
increased PCNA and Ki67 staining and MMP-13 expression
[172–175]. This was followed by the cellular changes similar
to those observed in hypertrophic zone of the growth plate
as indicated by type X collagen production, collagenaseArthritis 5
and alkaline phosphatase staining, and increased type II
collagen cleavage activity in the mid-zone [172, 176]. Later,
chondrocyteactivationextendstothesuperﬁcial zone,where
it is accompanied by chondrocyte apoptosis evidenced by
t h ep r e s e n c eo ft h ec e l l sc a r r y i n gD N An i c k s[ 172]. IL-1β
expression is also upregulated both in the superﬁcial and
deep cartilage zones in early OA [177]. Similar to biphasic
MMP-13 expression in the growth plate, upregulation of this
collagenase in the articular cartilage was initially preceded
and later accompanied by type X collagen and alkaline
phosphatase expression [172, 176].
An early OA articular cartilage degeneration is observed
focally. Spatial distribution of chondrocyte diﬀerentiation-
related gene expression in the areas adjacent to and remote
from the early lesion also resembles that in the growth
plate and is associated with increased collagenase cleavage of
typeIIcollagen.Thus,collagenasesMMP-1, MMP-14 (MT1-
MMP), and aggrecanase ADAMTS-5 (but not ADAMTS-
4), cytokines IL-1α/β and TNF-α, chondrocyte terminal
diﬀerentiation-related genes COL10A1, MMP-13, MMP-9,
Ihh, and caspase 3 were often upregulated in the vicinity
of the lesion. Growth factors associated with growth plate
chondrocyte proliferation, namely, FGF-2, PTHrP, and TGF
β1/2, as well as the matrix molecules COL2A1 and aggrecan,
were expressed adjacent to and remote from the lesion
[22]. In addition, a distinct spatial reorganization in human
superﬁcial chondrocytes in remote area from early OA
lesions has been recently reported [178].
However, of all genes, only caspase 3 and ADAMTS-
5 expression was exclusively seen in association with early
lesions. Elevation of collagenase activity was associated with
afrequentelevationofexpressionofCOL10A1,caspase3,IL-
1α/β,MMP-1,andADAMTS-5andadecreasedexpressionof
Sox-9, TGF-β1, TGF-β2, TNF-α, and aggrecan [22].
Moderate OA changes in the articular cartilage (Mankin
6–9), which are characterized by the lack of ﬁbrillations,
some loss of superﬁcial zone, and some clustering of cells
[163, 171], are associated with the increase of PCNA staining
in the superﬁcial zone and annexin VI and VIII antigen
upregulation in the mid- and deep zones [160, 163, 179].
Therefore, articular chondrocyte activation in early OA,
which is the most pronounced in the superﬁcial and mid-
zones, resembles that observed during chondrocyte matura-
tion in the growth plate.
6.Gene Expressionin Late
OsteoarthriticCartilage
Severe OA (Mankin ≥10) is characterized by extensive
ﬁssuring andﬁbrillation,clusteringofchondrocytes,andloss
of cartilage [163]. Cartilage zonal organization is disturbed.
The superﬁcial zone degradation produces rough ﬁbrillated
surface, ﬁssures, and cracks extending to the calciﬁed zone.
This is accompanied by severe proteoglycan loss followed
by degradation of type II collagen [164, 180]. Collagen
degradation occurs around chondrocytes. At this time,
upregulation of MMPs-13, -2, -11, ADAMTS as well as
expression of collagens type I, II, III, VI, and X were
observed near the articular surface [148, 181–183]a n dw a s
accompanied by strong expression of IL-1β and TNFα [149].
At the same time, collagen replenishment is limited as Col2A
N-propeptide, a marker of collagen synthesis, was detected
only in the deep zone close to subchondral bone [184].
As it was stated above, all these gene activities have been
also observed in the hypertrophic zone of the fetal growth
plate.
Chondrocyte terminal diﬀerentiation-related gene
expression is also observed in cell clusters located around
ﬁssures [185, 186]. In these clusters, both collagen type II
and X synthesis [187]a sw e l la sT G F β3 and its receptor
regulator Smad-2P expression were observed [188].
PCNA and syndecan-3, the markers of early fetal
chondrocyte diﬀerentiation, as well as annexin VI and
alkaline phosphatase, which are involved in terminal stage
of diﬀerentiation, all are upregulated near articular surface
in human OA articular cartilage [30, 163]. At the same time,
annexin VIII and osteocalcin, which were never detected in
normal articular cartilage, were observed in the mid- and
deep zones in late OA cartilage [30, 160]. An increase in
BMP-2 expression [188] was associated with upregulation
of tumor suppressor p53 expression [189] and cyclin-
dependentkinase inhibitor p16INK4aupregulationin all the
cartilage zones [155] indicating inhibition of proliferative
potential in late OA chondrocytes. However, repression of
antiproliferativefactorTob1hasbeenalsoreportedinthelate
s t a g eo fk n e eO Ac a r t i l a g e[ 183].
The most severely damaged rodent knee OA articu-
lar cartilage has shown signiﬁcantly reduced expression
of proliferation-related growth factors and their signaling
molecules such as PTHrP, TGFβ3a n dS m a d - 2 P ,T G F β1
and its receptor II [188, 191]. However, in human hip OA,
both downregulation and upregulation of TGFβ1–3 isoform
expression compared to healthy cartilage have been reported
[43, 192], while one study failed to detect any upregulation
of chondrocyte diﬀerentiation and hypertrophy markers
associated with late OA [193].
Antiangiogenic factor chondromodulin-1 downregula-
tion concomitantto VEGF upregulationindicating increased
vascular invasion into cartilagein advanced OA has beenalso
observed [194, 195]. This was accompanied by upregulation
of chondrocyte apoptosis, a marker of the ﬁnal step of
chondrocyte diﬀerentiation, which was more pronounced in
OA cartilage compared to normal specimens [189].
Overall degrading activity prevailed over synthesis as
serum levels of Col2A N-propeptide were lower than that of
collagen degradation products in late OA patients compared
to controls indicating the uncoupling of collagen synthesis
and degradation in OA [190]. Moreover, serum increase
in both Col2A N-propeptide and collagen degradation
fragments was often indicativeonthe most aggressive disease
progression [196].
Thus, the similarity in the gene expression proﬁles asso-
ciated with matrix destruction in OA articular cartilage and
in the hypertrophic zone of the growth plate observed in the
majority of studies suggests an acquisition of hypertrophic




The similarity of ECM degradation in OA to that in the
hypertrophic zone of primary growth plate involves upregu-
lation of type II collagen cleavage by collagenase and expres-
sion of regulatory diﬀerentiation-related growth factors and
matrix proteins, which are associated with chondrocyte
hypertrophy [6, 22, 25, 28]. Therefore, the aboveobservation
that hypertrophic changes in the growth plate chondrocytes
are reversible [112] suggests a possibility for OA articular
chondrocytes to regain healthier phenotype when they are
treated by the agents inhibiting fetal hypertrophy.
In fact, the same growth factors, namely, TGFβ2, FGF-
2, and insulin, which were previously used individually or in
combination to suppress hypertrophy in growth plate chon-
drocytes [112], have been shown to be capable of arresting
type II collagen cleavage,chondrocyte diﬀerentiation-related
gene, and proinﬂammatory cytokine expression in human
OA articular cartilage explants [197]. Another combination
ofTGFβ1 and IGF1 inhibited collagendegradation, a marker
of extracellular matrix destruction, which was induced
by oncostatin M and TNFα in bovine articular cartilage
[198]. It has been also shown that TGFβ inhibition of
chondrocyte diﬀerentiation is likely mediated by Smad2/3
pathway through modulation of Runx2 function [75]. In
another study, a major proliferation-related growth factor
PTHrP downregulated terminal diﬀerentiation-related genes
in cultured mineralizing articular chondrocytes from the
deep zone as well as in chondrogenic articular cartilage con-
structs[199,200].Itisworthtonoteherethatgrowthfactors,
which were capable of inhibiting collagen degradation in
OA articular cartilage, are predominantly expressed in the
proliferative zone of the growth plate and are required for
chondrocyte proliferation in the development.
Similareﬀectonsuppressionofcollagencleavageinasso-
ciation with inhibition of chondrocyte hypertrophy-related
genes and proinﬂammatory cytokines IL-1β and TNFα
has been observed on treatment of OA explants with low
concentrations of PGE2 [201]. Although PGE2 is expressed
in all the growth plate zones, it is primarily required for
fetal chondrocyte proliferation [137]a n di sc a p a b l ea l s o
of inhibiting their terminal diﬀerentiation [134, 135]a n d
expression of proinﬂammatory mediators [202]. At the same
time, PGE2 at higherconcentrations hasbeenshown toexert
stimulating eﬀects on cartilage degradation [203].
Alternatively, downregulation of the genes, which are
expressed in the hypertrophic zone of the growth plate and
associated with chondrocyte terminal diﬀerentiation such
as Hedgehog signaling, TGFβ1/BMP signaling, transform-
ing growth factor-beta-activated kinase (TAK) 1, cyclin-
dependent kinase inhibitor p16INK4a, ADAMTS5, RUNX2,
and caspases, resulted in abrogation of matrix degeneration,
less type X collagen production, and MMP-13 expression
[155, 204–210]. Therefore, upregulation of the genes asso-
ciated with growth plate chondrocyte proliferation or down-
regulation of hypertrophy-related genes favors acquisition of
healthier phenotype in OA articular chondrocytes.
However, while direct inhibition of cartilage degradation
by the agents capable of regulating chondrocyte diﬀerentia-
tion is an attractive means to counteract articular cartilage
degeneration in OA, it has several limitations. Thus, fol-
lowing the inhibition of cartilage degradation by individual
growth factors (GFs) reparation of articular cartilage in OA
in vivo may require a combination of GF [18, 211, 212]. For
example, being the most eﬃcientinsuppressing OA articular
cartilage destruction [197], TGFβ2a l o n em a yn o tb ec a p a b l e
of restoring the anabolic functions of healthy articular
cartilage since it has been reported to downregulate type
II collagen and aggrecan synthesis [108, 213]. In contrast,
in responsive individuals, insulin may facilitate tissue repair
as it is a principal anabolic agent in the articular cartilage
[214]. FGF-2 can also promote cartilage repair [212]b y
itself or inducing local TGFβ or its own expression [215].
In addition, combinations of these and other growth factors
havebeen shown toproducesynergistic eﬀectin maintaining
synthesis of matrix molecules in articular and growth plate
chondrocytes [108, 216, 217].
Another concern on GF application is related to their
possible catabolic eﬀects. Although no evidence has been
obtained that TGFβ2 can act catabolically in human OA
articular cartilage [197], destructive potential of this growth
factorathighconcentrationwasobservedinnormalarticular
cartilage in vivo after its intraarticular injections, which
produced joint swelling, ﬁbroblastic proliferation of synovial
membrane, and profound loss of articular cartilage pro-
t e o g l y c a ni nr a b b i tj o i n t s[ 213]. Therefore, the delivery of
exact therapeutic amount of the growth factor to the site of
articular cartilage destruction may be important. This has
beendemonstrated ina recent study, where deleteriouseﬀect
of TGFβ1 capable of inducing synovial ﬁbrosis has been
counteracted by combined overexpression of TGFβ1a n di t s
inhibitor Smad7 [188]. This resulted both in prevention of
proteoglycan (PG) loss and in increase in PG content in
mouse OA cartilage.
8.Modeling of OA-Related Changes in Healthy
ArticularCartilageIsAssociated with
Chondrocyte HypertrophyDevelopment
In healthy adult articular cartilage, chondrocyte diﬀeren-
tiation does not occur in the noncalciﬁed cartilage [218].
However, when maturational arrest is abolished, chondro-
cyte diﬀerentiation-related genes, which are barely expressed
in healthy articular cartilage, become upregulated followed
by hypertrophic changes in thecells and extracellular matrix.
If this notion is true, stimulation of degradation in healthy
articular cartilage should be accompanied by chondrocyte
hypertrophy development. The relieve of transcriptional
repression can be attained by cartilage treatment with
azacytidine C (Aza-C), which replaces cytidine bases in
genomic DNA during replication and disturbs methylation
pattern of cytidines (CpG islands) in target gene promoters.
This was associated with upregulation of PTHrP, governing
chondrocyte proliferation in the growth plate, as well as
chondrocyte hypertrophy-related collagen type X, Ihh, andArthritis 7
alkaline phosphatase gene expression, and the increase in
chondrocyte cell size in healthy articular cartilage [219–221].
On the other hand, alterations associated with chondro-
cyte hypertrophy in the growth plate are always accompa-
nied by overt extracellular matrix resorption producing its
degradation fragments [3]. Therefore, it is not surprising
that collagenand/orﬁbronectin degradationpeptides, which
can be also released on mechanical destruction of articular
cartilage caused by trauma or joint overload in case of
anterior cruciate ligament transection, have been shown to
be capable of inducing articular cartilage degradation by
upregulation of collagenase and MMPs activity [222–224].
Besides, these peptides upregulated chondrocyte prolifer-
ation, production of type X collagen and apoptotic cells
on the surface of articular cartilage explants [172, 224].
Collagen fragments may also account for OA-like changes
induced in healthy cartilage by overexpression of MMP-
13, which were associated with chondrocyte hypertrophy
in mouse articular cartilage [47]. In addition, other matrix
disturbances such as lack of matrilin-3 by a corresponding
geneknockoutproducedprematurechondrocytematuration
to hypertrophy and formed predisposition to develop severe
OA in mice [141].
Functional disturbances in the regulatory genes involved
in chondrocyte diﬀerentiation can also produce OA-related
changes in healthy articular cartilage resembling chondro-
cyte maturation in the growth plate. Thus, deﬁciency in
TGFβ signaling, which is essential for articular cartilage
maintenance and had been induced either by overexpression
of functionless TGFβ type II receptor [225] or by deletion of
Smad3 signaling [104, 226], caused accelerated chondrocyte
diﬀerentiation associated with type X collagen expression
and OA-like changes in articular cartilage. It has been also
shown that the absence of signaling through Fgfr (ﬁbroblast
growth factor receptor) 3 in the joints of Fgfr3(−/−)
mice produced premature cartilage degeneration and early
arthritis [227]. In contrast, TGFalpha signaling suggests
catabolic potential of this growth factor as it has been shown
to stimulate articular chondrocyte proliferation, formation
of cell clusters followed by expression of matrix-degrading
enzymes MMP-13, cathepsin C and downregulation of Sox9,
as well as collagen and aggrecan expression in rat articular
osteochondral explants [228].
Being an important factor of OA articular cartilage
pathology proinﬂammatory cytokines such as TNFα and IL-
1β have been shown to mediate articular cartilage degrada-
tionbyupregulationofmatrix-degradingMMPs[229].Ithas
been observed recently that increased expression of proin-
ﬂammatory agents such as TNFα,c h e m o k i n e sI L - 8 ,g r o w t h -
related oncogene α (GROα), or the multiligand receptor
for advanced glycation end products (RAGE) induced also
chondrocyte hypertrophy evidenced by collagen type X
expression [230, 231]. This suggests a link between inﬂam-
mation and altered diﬀerentiation in articular chondrocytes
[231]. Interestingly, the impairment TGFβ signaling by IL-
1β was mediated by downregulation of TGFβRII [232]. The
loss of function of this receptorhas previously been linked to
chondrocyte hypertrophy induction and OA developmentin
animal studies [225].
Therefore, OA-like alterations in healthy articular car-
tilage induced by the mediators, which are upregulated in
the hypertrophic zone during endochondral ossiﬁcation,
are accompanied by ECM degradation and associated with
articular chondrocyte hypertrophy.
9.Conclusions
The data presented here shows a signiﬁcant progress in
our understanding of molecular mechanisms of articular
cartilage degradation in OA. They involve at least in part
similar machinery of extracellular matrix resorption in
the hypertrophic zone of the growth plate and in OA
articular cartilage in the course of its degeneration. The
observation that profound cellular phenotypic changes in
articular chondrocytes occur prior the overt cartilage matrix
degradation monitored histologically suggests that articular
chondrocyte phenotype modiﬁcations can be recognized
very early in the disease at gene expression level favoring
timely disease recognition, which could help its prevention.
This implies also innovative opportunities in suppression of
cartilage matrix degradation targeting inhibition of chon-
drocytehypertrophy andsuggestsnewtargetsfortherapeutic
intervention. For this purpose, further studies are required
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